



Tranexamic Acid
MEDICATION REFERENCE CARD

INDICATION	<ul style="list-style-type: none"> Adults, who sustained blunt or penetrating trauma occurring within 3 hours with signs and symptoms of hemorrhagic shock and one or more of the following: <ul style="list-style-type: none"> Systolic blood pressure of less than 90 mmHg at scene of injury, during ground medical transport, or on arrival to designated trauma centers. Bleeding uncontrolled by direct pressure or tourniquet. Significant blood loss and a heart rate greater than 120 BPM.
CONTRAINDICATION	<ul style="list-style-type: none"> Age < 15 years old. Any patient with an active thromboembolic event (within the last 24 hours), i.e., active stroke, myocardial infarction or pulmonary embolism. Any patient with a hypersensitivity or anaphylactic reaction to TXA. Any patient more than three (3) hours post injury. Traumatic arrest with greater than five (5) minutes of CPR without return of vital signs. Penetrating cranial injury. Traumatic brain injury with brain matter exposed. Isolated drowning or hanging victims. Documented cervical cord injury with motor deficit.
SIDE EFFECTS	<ul style="list-style-type: none"> Thromboembolism (DVT and pulmonary embolism) Gastrointestinal effects including nausea, vomiting and diarrhea Headache Fatigue Dizziness Visual disturbances
ADULT DOSE	<ul style="list-style-type: none"> 1 gram in 100 mL NS IV/IO over 10 min (NO IV PUSH).
PEDIATRIC	<p>***NOT LOCALLY INDICATED FOR PEDIATRIC PATIENTS***</p>
CAUTION	<ul style="list-style-type: none"> Patients with thromboembolism risk Patients with renal impairment Patients with history of upper urinary tract bleeding
ACTIONS	<ul style="list-style-type: none"> A synthetic derivative of lysine that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen. Inhibits both Plasminogen activation and Plasmin activity thus preventing clot breakdown.
GUIDELINE	<ul style="list-style-type: none"> T-03 Major Hemorrhage Control